Sirolimus-Eluting Stent vs. Intravascular Brachytherapy in In-Stent Restenotic Coronary Artery Lesions(SISR)
Launched by CORDIS CORPORATION · Sep 30, 2005
Trial Information
Current as of June 18, 2025
Completed
Keywords
ClinConnect Summary
No description provided
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • 1. The patient has an in-stent restenosis of \> 50% (by subjective angiographic determination of the minimal luminal diameter compared to the distal reference diameter) within a native coronary artery which has previously undergone stent placement ( 4 weeks). Lesions must meet ISR Classification I-III.
- • 2. The patient has a history, signs of, or laboratory studies that suggest coronary ischemia attributable to the target stenosis. The diagnosis of angina pectoris is defined by Canadian Cardiovascular Society Classification (CCS I, II, III, or IV) OR unstable angina pectoris (Braunwald Classification B\&C, I-II) OR patients with documented silent ischemia;
- • 3. The study target lesion must be located in an in-stent restenotic native coronary artery measuring \> 2.75mm and 3.5mm in diameter and \> 15mm and 40mm in length to allow treatment with a maximum of three 18mm stents. The target lesion must have undergone coronary interventional treatment \> 4 weeks previously. Patients with one or more prior percutaneous coronary interventions at the target lesion are acceptable candidates.
- • 4. The vessel 1cm distal to the target lesion is \> 2.5mm in diameter;
- • 5. Ejection Fraction must be \> 40%;
- • 6. The study target lesion cannot be located in a vessel containing a second lesion requiring treatment at the time of the procedure.
- • 7. Male or non-pregnant female patients \> 18 years of age inclusive. NOTE: Females of child-bearing potential must have a negative pregnancy test (urine or serum) prior to enrollment and must use birth control for 6 months.
- Exclusion Criteria:
- • 1. The study target lesion has definite or possible thrombus present by angiographic criteria.
- • 2. The patient has experienced a Q-wave or non-Q-wave myocardial infarction with documented total CK \> 2 times normal within the preceding 24 hours and the CK and CK-MB enzymes remain above normal at the time of treatment.
- • 3. Impaired renal function (Serum creatinine \> 2.0mg/dl);
- • 4. The patient has unstable angina classified as Braunwald III B or C, or is having peri infarction angina.
- • 5. The left ventricular ejection fraction is \< 40%.
- • 6. The target vessel has previously sustained a perforation.
- • 7. Totally occluded vessel (TIMI 0 level);
- • 8. Prior stent within 5mm of target lesion;
- • 9. There is a total occlusion of the restenosed-stent (ISR Classification IV) prior to the interventional procedure.
- • 10. Has an ostial target lesion;
- • 11. Significant (\> 50%) in-stent restenoses proximal or distal to the target lesion that might require revascularization or impede runoff;
About Cordis Corporation
Cordis Corporation is a leading global provider of innovative cardiovascular and endovascular solutions, dedicated to advancing the treatment of vascular diseases. With a strong emphasis on research and development, Cordis focuses on delivering high-quality medical devices that enhance patient outcomes and improve procedural efficiency. The company is committed to clinical excellence and rigorous regulatory compliance, actively engaging in clinical trials to support the safety and efficacy of its products. Through collaboration with healthcare professionals and continuous innovation, Cordis aims to address unmet medical needs and foster advancements in the field of interventional medicine.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Rochester, Minnesota, United States
Patients applied
Trial Officials
David R. Holmes, Jr., MD
Principal Investigator
Mayo Clinic - Rochester, Minnesota
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials